drug
as of 2026-07-01Rituximab
MeSH D000069283
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Region Örebro County
4 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
SchizophreniaAutoimmune EncephalitisSchizo Affective DisorderBrief Psychotic DisorderObsessive-Compulsive DisorderUnspecified PsychosisPsychosisTreatment-resistant SchizophreniaSchizophrenia Spectrum and Other Psychotic DisordersCompulsive BehaviorMental DisordersSchizophreniaSchizophrenia, Treatment-ResistantOther PsychosesAutoimmune Diseases of the Nervous SystemDelusional Disorder
Trials
4
Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement
NCT04323566Phase 2Enrolling By Invitation
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
NCT03194815Phase 2Active Not Recruiting
A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults
NCT05622201Phase 2Active Not Recruiting
Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)
NCT03983018Phase 2Completed
KOLs & investigators
3
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication
indication
indication
KOL
Janet L Cunningham, MD PhD
personKOL score 6
Susanne Bejerot, MD, PhD
personKOL score 5
Alasdair Coles, PhD FRCP
personKOL score —